Surface Logix has announced the commencement of a company-sponsored Phase IIa
clinical trial for SLx-2101, a new potent and selective long-acting, oral PDE5
inhibitor. SLx-2101 is being evaluated for the treatment of vascular and cardiovascular
disease where endothelial dysfunction is a significant component of the pathogenesis
of the disease.
This study will assess the safety, tolerability and efficacy of different single doses of SLx-2101 in patients with erectile dysfunction who are known to respond to the marketed PDE5 inhibitors. The study was designed to establish the dose response and the duration of action of SLx-2101 in patients as suggested by a Phase I study which demonstrated that SLx-2101 has an extended half-life and pharmacodynamic activity in healthy subjects.